ÖZEN, A. O. Et Al. 2024. Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study. The Lancet , vol.403, no.10427 , 645-656.

ÖZEN, A. O., Chongsrisawat, V., Sefer, A. P., KOLUKISA, B., Jalbert, J. J., Meagher, K. A., ... Brackin, T.(2024). Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study. The Lancet , vol.403, no.10427, 645-656.

ÖZEN, AHMET Et Al. "Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study," The Lancet , vol.403, no.10427, 645-656, 2024

ÖZEN, AHMET O. Et Al. "Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study." The Lancet , vol.403, no.10427, pp.645-656, 2024

ÖZEN, A. O. Et Al. (2024) . "Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study." The Lancet , vol.403, no.10427, pp.645-656.

@article{article, author={AHMET OĞUZHAN ÖZEN Et Al. }, title={Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study}, journal={The Lancet}, year=2024, pages={645-656} }